LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
The narrative around Zedge has shifted as our fair value estimate edges up to $6.00 from $5.00, alongside a slightly higher discount rate of about 8.21% versus 8.00% and a modest uplift in expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback